16 completed, 4 unknown, 3 recruiting, 2 active not recruiting. 10 Phase 3, 8 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Unknown 1 |
| Phase 2 | 8 | Completed 5, Active not recruiting 1, Recruiting 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Complicated Urinary Tract Infection: new trials by email Literature Review of Complicated Urinary Tract Infection trials Research Report on Complicated Urinary Tract Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR Complicated Urinary Tract Infection | Active not recruiting | QIAGEN Gaithersburg, Inc | 1500 | 2025-12-23 | 2026-11-02 | |
| A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis Meropenem-Vaborbactam, Antibiotics - Acute Pyelonephritis, Complicated Urinary Tract Infection | Phase 2 | Active not recruiting | Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) | 66 | 2025-06-03 | 2026-09-10 |
| A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection | Recruiting | Pfizer | 600 | 2024-02-19 | 2026-09-08 | |
| Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) WCK 4282 (FEP-TAZ) 4 g, Meropenem, ciprofloxacin 500 mg Optional Oral Switch - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Unknown | Wockhardt | 1004 | 2024-01-01 | 2023-07-17 |
| P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 126 | 2023-09-22 | 2026-04-13 |
| A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI cefepime and enmetazobactam combination - Complicated Urinary Tract Infection | Phase 2 | Recruiting | Orchid Pharma Europe GmbH | 40 | 2023-09-11 | 2026-08-20 |
| Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Meiji Seika Pharma Co., Ltd. | 614 | 2023-05-23 | 2025-12-24 |
| Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Cefepime-zidebactam (FEP-ZID), Meropenem - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Wockhardt | 530 | 2022-08-28 | 2026-05-22 |
| Evaluating UTI Outcomes in at Risk Populations Urinary Tract Infections, Complicated Urinary Tract Infection | Completed | Pathnostics | 7921 | 2022-07-18 | 2024-05-03 | |
| Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children Benzylpenicillin - single dose, Benzylpenicillin - three days, Gentamicin - single dose - Complicated Urinary Tract Infection, Infection | Phase 4 | Recruiting | Murdoch Childrens Research Institute | 396 | 2022-05-30 | 2026-10-09 |
| Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections Meropenem- FL058, Piperacillin -tazobactam, Saline - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Unknown | Qilu Pharmaceutical Co., Ltd. | 150 | 2021-10-08 | 2021-09-29 |
| Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis Acute Pyelonephritis, Complicated Urinary Tract Infection | Unknown | Thomayer University Hospital | 90 | 2020-06-24 | 2023-01-06 | |
| Efficacy of Intravenous Fosfomycin in the Treatment of Complicated Urinary in Real-life Conditions. Drug: Intravenous fosfomycin, Drug: Intravenous quinolone or beta-lactam - Complicated Urinary Tract Infection | Unknown | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 400 | 2019-10-21 | 2019-11-14 | |
| Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) TBPM-PI-HBr, Ertapenem, Dummy Infusion - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Spero Therapeutics | 1372 | 2019-06-03 | 2022-07-25 |
| MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034) Ceftolozane/Tazobactam, Meropenem - Complicated Urinary Tract Infection, Pyelonephritis | Phase 2 | Completed | Merck Sharp & Dohme LLC | 134 | 2018-04-26 | 2023-05-06 |
| Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections Sulbactam-ETX2514, Placebo, Imipenem-cilastatin - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 2 | Completed | Entasis Therapeutics | 80 | 2018-01-17 | 2020-01-22 |
| Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) Imipenem+Cilastatin/Relebactam - Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 83 | 2017-10-04 | 2021-02-12 |
| Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) - Urinary Tract Infection (UTI), Complicated Urinary Tract Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 115 | 2016-04-14 | 2019-02-05 |
| A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) plazomicin, meropenem, levofloxacin (oral) - Complicated Urinary Tract Infection, Acute Pyelonephritis | Phase 3 | Completed | Achaogen, Inc. | 609 | 2016-01-11 | 2018-08-23 |
| Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care Use of C-reactive protein (CRP) point of care test, Brief intervention and parent leaflet, Finger Pulse Oximeter - Sepsis, Bacteraemia | Not applicable | Completed | KU Leuven | 8962 | 2013-01-01 | 2015-02-18 |
Showing 20 of 26. Sign in to see all of them.
Pyelonephritis (5) · Urinary Tract Infections (3) · Abscess (1) · Bacterial Infections (1) · Cellulitis (1) · Escherichia coli Infections (1) · Healthcare-Associated Pneumonia (1) · Infections (1) · Meningitis (1) · Osteomyelitis (1) · Pneumonia (1) · Sepsis (1) · Toxemia (1)
Infections (7) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Male Urogenital Diseases (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Kidney Diseases (5) · Nephritis (5) · Nephritis, Interstitial (5) · Pyelitis (5) · Bacterial Infections and Mycoses (2) · Lung Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2)
Meropenem (4) · Cilastatin, Imipenem Drug Combination (3) · Levofloxacin (3) · Anti-Bacterial Agents (2) · Ceftazidime (2) · ceftolozane (2) · nacubactam (2) · plazomicin (2) · Cefepime (1) · Ciprofloxacin (1) · Crisis Intervention (1) · Ertapenem (1) · Gentamicins (1) · Metronidazole (1) · Oximetry (1)
Merck Sharp & Dohme LLC (3) · Pfizer (3) · Achaogen, Inc. (2) · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Meiji Seika Pharma Co., Ltd. (2) · Wockhardt (2) · Entasis Therapeutics (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Iterum Therapeutics, International Limited (1) · KU Leuven (1) · Murdoch Childrens Research Institute (1) · Orchid Pharma Europe GmbH (1) · Pathnostics (1) · QIAGEN Gaithersburg, Inc (1) · Qilu Pharmaceutical Co., Ltd. (1)
United States (9) · Poland (7) · Bulgaria (6) · Czechia (6) · Slovakia (6) · Georgia (5) · Estonia (4) · Hungary (4) · Latvia (4) · Mexico (4) · Romania (4) · Russia (4) · South Africa (4) · Spain (4) · China (3)
Ahmad Haidar, MD (1) · An de Sutter, PhD (1) · Anibal Calmaggi, MD (1) · Bert Aertgeerts, PhD (1) · Carole A Sable, MD (1) · David Melnick, MD (1) · Florian Wagenlehner, MD (1) · Frank Buntinx, PhD (1) · Huang Haihui, Professor (1) · Jan Hrbacek, PhD. (1) · Jan Y Verbakel, MD (1) · Laila Ibrahim (1)
PMID 23145859, PMID 25277457, PMID 25277543, PMID 25931244, PMID 26254472, PMID 26994090, PMID 27716201, PMID 27872067, PMID 27887579, PMID 27999024, PMID 28446129, PMID 28464828, PMID 29269559, PMID 29912399, PMID 30061279, PMID 30221827, PMID 30786187, PMID 30910899, PMID 31843995, PMID 32602065, PMID 33191112, PMID 33332545, PMID 35388666, PMID 36333682, PMID 36689671, PMID 37072778, PMID 37700689, PMID 42134354
2015 (1), 2016 (1), 2018 (1)